Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing

The introduction of effective systemic therapies has significantly changed the treatment of stage III and IV melanoma. Both immune checkpoint inhibitors and targeted therapies have improved recurrence-free survival in the adjuvant setting. Recent interest has sparked for neoadjuvant systemic therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: van Akkooi, Alexander C. J., Zijlker, Lisanne P., Wouters, Michel W. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148869/
https://www.ncbi.nlm.nih.gov/pubmed/35397089
http://dx.doi.org/10.1007/s40259-022-00525-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148869/
https://www.ncbi.nlm.nih.gov/pubmed/35397089
http://dx.doi.org/10.1007/s40259-022-00525-x

Ejemplares similares